Both targeted and next-generation sequencing have increasing relevance in the diagnosis, prognosis/risk stratification and therapies for solid tumors. In particular, identification of oncogenetic drivers through molecular testing can lead to targeted therapies that in some cases. yield significant clinical response, either in the upfront or relapsed setting. Additionally, the increase in genetic testing in patients with solid tumors has led to an increase in identification of underlying cancer predisposition syndromes. The identification of these syndromes is important both for their effects on cancer therapeutics and ongoing surveillance for the patient and any affected family members. This lecture will review currently used molecular diagnostic techniques and their incorporation into clinical practice in pediatric solid tumor oncology.
- Discuss the use of genetic testing in diagnosis and management of solid tumors
- Review FDA-approved and investigational molecularly targeted therapies for children with solid tumors
- Discuss the importance of germline evaluation in patients with pediatric solid tumors
This seminar focuses on oncology and was delivered at a virtual event titled, “Molecular Medicine in Solid Tumors,” on December 1, 2021.
Additional CHOP Resources:
By starting this module, you agree to our Content Disclaimer and Terms of Service.
If this is your first time attempting to login to the new website with an existing account, you will first need to reset your password before logging in.Lost Your Password?
**By selecting “Yes”, you consent to receive information from CHOP. Once you have decided to receive such communications, you may later decide to stop receiving these communications. If you want to stop receiving these communications, you may send an email message to firstname.lastname@example.org.